someone explain cagrilintide to me like I have not read a paper in years
Genuine question, and the title is the question: someone explain cagrilintide to me like I have not read a paper in years. Bought small deliberately because the evidence base is thin. That felt like the only defensible approach. Asked a question here that turned out to be based on a mechanism confusion. Three people…
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Went looking for independent results on this and found a handful across the whole site.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
satiety signalling rather than incretin signalling
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Yes. The combination is where the interesting effect sizes are, and the monotherapy arms read very differently.
read the combination arms separately from the monotherapy arms
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
nothing here is approved as a standalone product and research material is not for human use
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.